Compare CHR & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHR | AEMD |
|---|---|---|
| Founded | 2016 | 1984 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 4.3M |
| IPO Year | 2018 | 2008 |
| Metric | CHR | AEMD |
|---|---|---|
| Price | $1.52 | $5.86 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 80.0K | ★ 2.4M |
| Earning Date | 07-28-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $105.44 | N/A |
| Revenue Next Year | $30.02 | N/A |
| P/E Ratio | $25.83 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.03 | $0.53 |
| 52 Week High | $2.95 | $35.97 |
| Indicator | CHR | AEMD |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 58.98 |
| Support Level | $1.51 | $3.20 |
| Resistance Level | $1.69 | $6.69 |
| Average True Range (ATR) | 0.13 | 0.34 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 14.29 | 0.89 |
Cheer Holding Inc is a provider of next generation mobile internet infrastructure and platform services in China. It is engaged in building a digital ecosystem that integrates platforms, applications, technology, and industry into a cohesive system, thereby creating a new, open business environment that leverages AI technology. Its portfolio includes various products and services, such as Polaris Intelligent Cloud, CHEERS Telepathy, CHEERS Open Platform, CHEERS Video, CHEERS e-Mall, CheerCar, CheerChat, CHEERS Fresh Group-Buying E-commerce Platform, Digital Innovation Research Institute, CHEERS Livestreaming, variety show series, IP short video matrix, and more.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.